Bitter pill to swallow for foreign investors in pharma

By Vikrant Kumar and Anina D’Cunha, L&L Partners
0
1675
LinkedIn
Facebook
Twitter
Whatsapp
Telegram
Copy link

Partially in response to a number of high-visibility inbound acquisitions in the Indian pharmaceutical sector, the government of India decided to bring brownfield acquisitions completely under the government approval route in November 2011. Greenfield acquisitions, however, remained under the automatic route. While granting approvals, the (then) Foreign Investment Promotion Board began imposing stringent conditions prohibiting non-compete restrictions on Indian parties and requiring the maintenance of status quo on production and supply of drugs and consumables in the national list of essential medicines and R&D expenditure. In the following years, these conditions were formally introduced to the foreign direct investment (FDI) policy. In June 2016, realizing the need to encourage brownfield FDI, the government decided to allow investment of up to 74% under the automatic route.

investors
Vikrant Kumar
Partner
Luthra & Luthra

Last year, the government also brought FDI in companies without operations or downstream investments under the automatic route. This was, however, subject to conditions that the intended activities of such companies should fall under sectors that are allowed under the automatic route and in sectors without foreign investment-linked performance conditions, which was defined as sector-specific conditions for FDI.

This leads to some interesting situations. If a minority Indian partner incorporates a joint venture company and the foreign partner subsequently infuses 74% capital into the venture over a few months, this raises the question whether the investment will be classified as greenfield or brownfield. Logically, one can argue that the investment should be classified as greenfield if the venture has yet to begin operations in earnest at the time of the investment. There is, however, another conundrum. Clearly, FDI in companies not having operations is permitted under automatic route only if intended activities also fall under automatic route and in sectors without FDI-linked performance conditions.

You must be a subscribersubscribersubscribersubscriber to read this content, please subscribesubscribesubscribesubscribe today.

For group subscribers, please click here to access.
Interested in group subscription? Please contact us.

你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章,欢迎成为我们的订阅会员成为我们的订阅会员

已有集团订阅,可点击此处继续浏览。
如对集团订阅感兴趣,请联络我们

Vikrant Kumar is a partner and Anina D’Cunha is an associate at L&L Partners. The views expressed are personal and intended for general information purposes. They are not a substitute for legal advice.

investors

L&L Partners

9th Floor, Ashoka Estate
Barakhamba Road
New Delhi – 110 001
India

Mumbai | Bengaluru | Hyderabad

Contact details
Tel: +91 11 4121 5100
Fax: +91 11 2372 3909
Email: delhi@luthra.com
Website: www.luthra.com

LinkedIn
Facebook
Twitter
Whatsapp
Telegram
Copy link